## Angelika Beate Riemer

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5203016/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Light contamination in stable isotope-labelled internal peptide standards is frequent and a potential source of false discovery and quantitation error in proteomics. Analytical and Bioanalytical Chemistry, 2022, 414, 2545-2552.	1.9	3
2	The Importance of Being Presented: Target Validation by Immunopeptidomics for Epitope-Specific Immunotherapies. Frontiers in Immunology, 2022, 13, 883989.	2.2	20
3	Bacterial peptides presented on tumour cells could be immunotherapy targets. Nature, 2021, 592, 28-29.	13.7	3
4	The shared frameshift mutation landscape of microsatellite-unstable cancers suggests immunoediting during tumor evolution. Nature Communications, 2020, 11, 4740.	5.8	78
5	Inducing Immunity Where It Matters: Orthotopic HPV Tumor Models and Therapeutic Vaccinations. Frontiers in Immunology, 2020, 11, 1750.	2.2	8
6	High-Throughput Prediction of MHC Class I and II Neoantigens with MHCnuggets. Cancer Immunology Research, 2020, 8, 396-408.	1.6	103
7	Abstract A33: High-throughput prediction of MHC Class I and Class II neoantigens with MHCnuggets. , 2020, , .		0
8	Performance Evaluation of MHC Class-I Binding Prediction Tools Based on an Experimentally Validated MHC–Peptide Binding Data Set. Cancer Immunology Research, 2019, 7, 719-736.	1.6	53
9	Enhanced Radiation Sensitivity of Human Papillomavirus-Driven Head and Neck Cancer: Focus on Immunological Aspects. Frontiers in Immunology, 2019, 10, 2831.	2.2	19
10	A non-functional neoepitope specific CD8 <sup>+</sup> T-cell response induced by tumor derived antigen exposure <i>in vivo</i> . Oncolmmunology, 2019, 8, 1553478.	2.1	16
11	Therapeutic vaccination using minimal HPV16 epitopes in a novel MHC-humanized murine HPV tumor model. Oncolmmunology, 2019, 8, e1524694.	2.1	8
12	Abstract 578: Investigation of the effect of hypoxia on presentation of HPV16-derived antigens - implications for therapeutic vaccine design. , 2019, , .		0
13	Abstract 578: Investigation of the effect of hypoxia on presentation of HPV16-derived antigens - implications for therapeutic vaccine design. , 2019, , .		0
14	A Targeted LCâ€MS Strategy for Lowâ€Abundant HLA Classâ€lâ€Presented Peptide Detection Identifies Novel Human Papillomavirus Tâ€Cell Epitopes. Proteomics, 2018, 18, e1700390.	1.3	27
15	Immune evasion mechanisms of human papillomavirus: An update. International Journal of Cancer, 2018, 142, 224-229.	2.3	93
16	MHCflurry: Open-Source Class I MHC Binding Affinity Prediction. Cell Systems, 2018, 7, 129-132.e4.	2.9	311
17	Abstract 721: Development of a therapeutic HPV vaccine based on mass spectrometry-verified target epitopes. , 2018, , .		0
18	ERAP1 overexpression in HPV-induced malignancies: A possible novel immune evasion mechanism. Oncolmmunology, 2017, 6, e1336594.	2.1	19

## Angelika Beate Riemer

#	Article	IF	CITATIONS
19	Analysis of Major Histocompatibility Complex-Bound HIV Peptides Identified from Various Cell Types Reveals Common Nested Peptides and Novel T Cell Responses. Journal of Virology, 2016, 90, 8605-8620.	1.5	18
20	Peptide Processing Is Critical for T-Cell Memory Inflation and May Be Optimized to Improve Immune Protection by CMV-Based Vaccine Vectors. PLoS Pathogens, 2016, 12, e1006072.	2.1	55
21	Identification of promiscuous HPV16-derived T helper cell epitopes for therapeutic HPV vaccine design. International Journal of Cancer, 2015, 136, 212-224.	2.3	22
22	Abstract LB-235: Therapeutic human papillomavirus vaccine design based on epitopes identified on the tumor cell surface by mass spectrometry. , 2015, , .		0
23	Abstract B31: Identification of target T cell epitopes for a therapeutic HPV16 vaccine. , 2015, , .		0
24	Abstract B32: Evaluation of toll-like receptor ligands as adjuvants for an epitope-based therapeutic HPV vaccine. , 2015, , .		0
25	Therapeutic Vaccine Strategies against Human Papillomavirus. Vaccines, 2014, 2, 422-462.	2.1	55
26	HPVdb: a data mining system for knowledge discovery in human papillomavirus with applications in T cell immunology and vaccinology. Database: the Journal of Biological Databases and Curation, 2014, 2014, bau031-bau031.	1.4	19
27	Common Concepts of Immune Defense. , 2014, , 219-266.		0
28	A vaccine targeting mutant IDH1 induces antitumour immunity. Nature, 2014, 512, 324-327.	13.7	613
29	Abstract 1267: Identification of HPV-derived CD4+ T-helper epitopes for improving therapeutic anti-HPV vaccine potency , 2013, , .		0
30	The Invisible Enemy – How Human Papillomaviruses Avoid Recognition and Clearance by the Host Immune System. The Open Virology Journal, 2012, 6, 249-256.	1.8	67
31	Identification and validation of reference genes for expression studies in human keratinocyte cell lines treated with and without interferonâ€Î³ – a method for <scp>qRT</scp> â€ <scp>PCR</scp> reference gene determination. Experimental Dermatology, 2012, 21, 625-629.	1.4	25
32	Abstract 3529: A direct mass spectrometry approach for HPV T cell epitope identification. , 2012, , .		0
33	Impaired tumor antigen processing by immunoproteasome-expressing CD40-activated B cells and dendritic cells. Cancer Immunology, Immunotherapy, 2011, 60, 857-867.	2.0	10
34	Abstract 902: Serum antibodies to the HPV16 proteome as biomarkers for head and neck cancer. , 2011, ,		0
35	3,3′,4,4′,5,5′-Hexahydroxystilbene Impairs Melanoma Progression in a Metastatic Mouse Model. Journal o Investigative Dermatology, 2010, 130, 1668-1679.	of 0.3	29
36	A Conserved E7-derived Cytotoxic T Lymphocyte Epitope Expressed on Human Papillomavirus 16-transformed HLA-A2+ Epithelial Cancers. Journal of Biological Chemistry, 2010, 285, 29608-29622.	1.6	71

Angelika Beate Riemer

#	Article	IF	CITATIONS
37	Mimotope vaccination – from allergy to cancer. Expert Opinion on Biological Therapy, 2009, 9, 493-506.	1.4	87
38	Active Induction of Tumor-Specific IgE Antibodies by Oral Mimotope Vaccination. Cancer Research, 2007, 67, 3406-3411.	0.4	43
39	Immunization with Mimotopes Prevents Growth of Carcinoembryonic Antigen–Positive Tumors in BALB/c Mice. Clinical Cancer Research, 2007, 13, 6501-6508.	3.2	26
40	Mimotopes for Active Immunotherapy of Tumors: Allergooncology. Clinical Immunology, 2007, 123, S9.	1.4	0
41	Mimotope vaccines: Epitope mimics induce anti-cancer antibodies. Immunology Letters, 2007, 113, 1-5.	1.1	41
42	Mimotopes identify conformational epitopes on parvalbumin, the major fish allergen. Molecular Immunology, 2006, 43, 1454-1461.	1.0	83
43	Small mimotopes are big in identifying B-cell epitopes. Blood, 2006, 108, 1794-1795.	0.6	1
44	Induction of IgG antibodies against the GD2 carbohydrate tumor antigen by vaccination with peptide mimotopes. European Journal of Immunology, 2006, 36, 1267-1274.	1.6	38
45	Characterization of GD2 Peptide Mimotope DNA Vaccines Effective against Spontaneous Neuroblastoma Metastases. Cancer Research, 2006, 66, 10567-10575.	0.4	63
46	Cross-reactivity of mimotopes with a monoclonal antibody against the high molecular weight melanoma-associated antigen (HMW-MAA) does not predict cross-reactive immunogenicity. Melanoma Research, 2005, 15, 111-117.	0.6	6
47	High-molecular-weight melanoma-associated antigen mimotope immunizations induce antibodies recognizing melanoma cells. Cancer Immunology, Immunotherapy, 2005, 54, 677-684.	2.0	29
48	Antiâ€ulcer drugs promote IgE formation toward dietary antigens in adult patients. FASEB Journal, 2005, 19, 1-16.	0.2	195
49	Vaccination With Cetuximab Mimotopes and Biological Properties of Induced Anti–Epidermal Growth Factor Receptor Antibodies. Journal of the National Cancer Institute, 2005, 97, 1663-1670.	3.0	79
50	Isolation and structural analysis of peptide mimotopes for the disialoganglioside GD2, a neuroblastoma tumor antigen. Molecular Immunology, 2005, 42, 319-325.	1.0	41
51	Matching of trastuzumab (Herceptin®) epitope mimics onto the surface of Her-2/neu – a new method of epitope definition. Molecular Immunology, 2005, 42, 1121-1124.	1.0	32
52	Generation of Peptide Mimics of the Epitope Recognized by Trastuzumab on the Oncogenic Protein Her-2/neu. Journal of Immunology, 2004, 173, 394-401.	0.4	95